ArticleInternational journal of molecular sciences2025
Potential of Apigenin, Berberine, Chrysin, and Luteolin to Overcome Doxorubicin Resistance in Acute Promyelocytic Leukemia HL-60 Cells.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ABCB6 promotes multidrug resistance in leukemia by mediating drug efflux.Blood science (Baltimore, Md.) · 2026Article
- Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach.Basic & clinical pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance (MDR) is one of the leading causes of high mortality in cancer. The NRF2 (Nuclear Factor Erythroid 2-Related Factor 2) transcriptional factor can play a major role in MDR development. In this study, we tested the NRF2 inhibitors-Apigenin, Berberine, Chrysin, and Luteolin (ABCL) for their ability to overcome doxorubicin resistance in acute promyelocytic leukemia HL-60 cells (HL-60/DOXO cells). We examined the effects of NRF2 inhibitors on cell viability, apoptosis, DNA damage, and reactive oxygen species (ROS) generation. Our results indicate that Apigenin, Chrysin, and Luteolin can effectively overcome doxorubicin resistance in HL-60/DOXO cells. On the contrary, Berberine does not demonstrate this activity and even hinders doxorubicin's activity. We hypothesize that the observed effects of ABCL may result from their interaction with the NRF2 factor, which is hyperactivated in the tested HL-60/DOXO cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.